구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BV (Induction with Brentuximab vedotin, Induction with Brentuximab vedotin (BV)) Seagen / Takeda·Hodgkin Lymphoma, Adult 119 trials |
|---|---|
Overview Program | Induction with Brentuximab vedotin (BV) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Hodgkin Lymphoma, Adult |
Overview Indication | Hodgkin Lymphoma, Adult |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | Vedotin: A Retrospective Cohort Study from a Te |
MoA Mechanism | Targeting the Urotensin II Receptor Pathway |
MoA Biomarker | biomarkers; however, these methods do not detect all HPV strains and are not applicable to HPV-negative tumor |
PK/PD Species | Mouse, Rat, The primary endpoint was safety |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat, The primary endpoint was safety |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.. In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib, a KRAS G12C inhibitor, and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (m… |
Clinical Safety signal | Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.. In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib, a KRAS G12C inhibitor, and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (m… |
Clinical Selected reported efficacy | ORR 78.3% |
Clinical Reported ORR | 78.3% |
Clinical Reported PFS | 16.5 |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT02453594 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02453594 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BV (Induction with Brentuximab vedotin, Induction with Brentuximab vedotin (BV)) Seagen / Takeda·Hodgkin Lymphoma, Adult 119 trials |
|---|---|
Overview Program | Induction with Brentuximab vedotin (BV) |
Overview Company | Seagen / Takeda |
Overview Modality | ADC |
Overview Target | Hodgkin Lymphoma, Adult |
Overview Indication | Hodgkin Lymphoma, Adult |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | Vedotin: A Retrospective Cohort Study from a Te |
MoA Mechanism | Targeting the Urotensin II Receptor Pathway |
MoA Biomarker | biomarkers; however, these methods do not detect all HPV strains and are not applicable to HPV-negative tumor |
PK/PD Species | Mouse, Rat, The primary endpoint was safety |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat, The primary endpoint was safety |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.. In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib, a KRAS G12C inhibitor, and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (m… |
Clinical Safety signal | Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.. In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib, a KRAS G12C inhibitor, and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (m… |
Clinical Selected reported efficacy | ORR 78.3% |
Clinical Reported ORR | 78.3% |
Clinical Reported PFS | 16.5 |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT02453594 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02453594 |
추천 비교
추천 비교